VICTORIA, BC, Sept. 4,
2024 /CNW/ - Eupraxia Pharmaceuticals Inc.
("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a
clinical-stage biotechnology company leveraging its proprietary
DiffuSphere™ technology to optimize drug delivery for applications
with significant unmet need, today announced that the Company will
be presenting at the upcoming H.C. Wainwright 26th Annual Global
Investment Conference being held in New
York, NY from September 9-11,
2024.
Presentation Details:
The Company's presentation is at 8:00 a.m. ET on Monday, September 9, 2024. Eupraxia invites
all interested parties to view the presentation by clicking on the
following link:
https://journey.ct.events/view/454db24e-98d2-44e8-b318-dd8c5ec820ee
A webcast of the presentation will also be available on the
Events and Presentations page of the Company's website here.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology designed to deliver targeted,
long-lasting activity with fewer side effects. DiffuSphere™, a
proprietary, polymer-based micro-sphere technology, is designed to
facilitate targeted drug delivery, with extended duration of
effect, and offers multiple, highly tuneable pharmacokinetic (PK)
profiles. This investigational technology can be engineered for use
with multiple active pharmaceutical ingredients and delivery
methods.
Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment
of eosinophilic esophagitis ("EoE"). EP-104GI is administered as an
injection into the esophageal wall, providing local delivery of
drug. This is a unique treatment approach for EoE. Eupraxia also
recently completed a Phase 2b
clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain
due to osteoarthritis of the knee. The trial met its primary
endpoint and three of the four secondary endpoints. In addition,
Eupraxia is developing a pipeline of later and earlier-stage
long-acting formulations. Potential pipeline indications include
candidates for other inflammatory joint indications and oncology,
each designed to improve on the activity and tolerability of
currently approved drugs. For further details about Eupraxia,
please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and
Information
This news release includes forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "suggests", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes", "potential"
or variations (including negative and grammatical variations) of
such words and phrases, or state that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved. Forward-looking statements in this news release
include statements regarding the details of the Company's
presentation at the upcoming H.C. Wainwright 26th Annual
Global Investment Conference; the Company's product candidates,
including their expected benefits to patients with respect to
safety, efficacy, duration and tolerability; the results gathered
from studies and trials of Eupraxia's product candidates; the
potential for the Company's technology to impact the drug delivery
process; potential market opportunity for the Company's products;
and potential pipeline indications. Such statements and information
are based on the current expectations of Eupraxia's management, and
are based on assumptions, including but not limited to: future
research and development plans for the Company proceeding
substantially as currently envisioned; industry growth trends,
including with respect to projected and actual industry sales; the
Company's ability to obtain positive results from the Company's
research and development activities, including clinical trials; and
the Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties
related to the Company's limited operating history; the Company's
novel technology with uncertain market acceptance; if the Company
breaches any of the agreements under which it licenses rights to
its product candidates or technology from third parties, the
Company could lose license rights that are important to its
business; the Company's current license agreement may not provide
an adequate remedy for its breach by the licensor; the Company's
technology may not be successful for its intended use; the
Company's future technology will require regulatory approval, which
is costly and the Company may not be able to obtain it; the Company
may fail to obtain regulatory approvals or only obtain approvals
for limited uses or indications; the Company's clinical trials may
fail to demonstrate adequately the safety and efficacy of its
product candidates at any stage of clinical development; the
Company may be required to suspend or discontinue clinical trials
due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for
its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical
research services; the Company may not be able to successfully
execute its business strategy; the Company will require additional
financing, which may not be available; any therapeutics the Company
develops will be subject to extensive, lengthy and uncertain
regulatory requirements, which could adversely affect the Company's
ability to obtain regulatory approval in a timely manner, or at
all; the impact of health pandemics or epidemics on the Company's
operations; the Company's restatement of its consolidated financial
statements, which may lead to additional risks and uncertainties,
including loss of investor confidence and negative impacts on the
Company's common share price; and other risks and uncertainties
described in more detail in Eupraxia's public filings on SEDAR+
(sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302237665.html
SOURCE Eupraxia Pharmaceuticals Inc.